DHA and EPA Down-regulate COX-2 Expression through Suppression of NF-kappa B Activity in LPS-treated Human Umbilical Vein Endothelial Cells
The Korean Journal of Physiology and Pharmacology
; : 301-307, 2009.
Article
in En
| WPRIM
| ID: wpr-727520
Responsible library:
WPRO
ABSTRACT
Inflammatory processes of vascular endothelial cells play a key role in the development ofatherosclerosis. We determined the anti-inflammatory effects and mechanisms of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) on LPS-treated human umbilical vein endothelial cells (HUVECs) to evaluate their cardioprotective potential. Cells were pretreated with DHA, EPA, or troglitazone prior to activation with LPS. Expression of COX-2, prostaglandin E2 (PGE2) and IL-6 production, and NF-kappaB activity were measured by Western blot, ELISA, and luciferase activity, respectively. Results showed that EPA, DHA, or troglitazone significantly reduced COX-2 expression, NF-kappaB luciferase activity, and PGE2 and IL-6 production in a dose-dependent fashion. Interestingly, low doses (10 micrometer) of DHA and EPA, but not troglitozone, significantly increased the activity of NF-kappaB in resting HUVECs. Our study suggests that while DHA, EPA, and troglitazone may be protective on HUVECs under inflammatory conditions in a dose-dependent manner. However there may be some negative effects when the concentrations are abnormally low, even in normal endothelium.
Key words
Full text:
1
Database:
WPRIM
Main subject:
Enzyme-Linked Immunosorbent Assay
/
Dinoprostone
/
Eicosapentaenoic Acid
/
Blotting, Western
/
Chromans
/
NF-kappa B
/
Interleukin-6
/
Endothelial Cells
/
Thiazolidinediones
/
Endothelium
Limits:
Humans
Language:
En
Journal:
The Korean Journal of Physiology and Pharmacology
Year:
2009
Document type:
Article